(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
The Best 10 Innovation Developments of the Year - 2Who is Adm. Frank 'Mitch' Bradley and what does he have to do with the Venezuela boat strikes?
- 3Affordable Care Act enrollment is slightly ahead of last year, despite expiring subsidies
- 4US FDA approves Kura-Kyowa's blood cancer therapy
- 52 new malaria treatments announced as drug resistance grows
- American tourists left stranded in the Caribbean following flight cancellations after airspace closed for Maduro operation
- New ‘Cloud-9’ object could reveal the secrets of dark matter
- Which Diet Prompts the Incomparable Wellbeing Results?
- How do my eyes adjust to the dark and how long does it take?
- Interstellar comet 3I/ATLAS' journey through our solar system, in photos
- Grasping the Qualifications Among Separation and Dissolution
- Storm Goretti sweeps United Kingdom, France with winds over 120 mph
- Instructions to Upgrade the Mechanical Highlights of Your Shrewd Bed for a Superior Night's Rest
- German politician urges more face-to-face interaction in digital age
